- Prospective Studies Collaboration
- Lewington S.
- Whitlock G.
- Clarke R.
- Sherliker P.
- Emberson J.
- Halsey J.
- Qizilbash N.
- Peto R.
- Collins R.
- Cholesterol Treatment Trialists' (CTT) Collaboration
- Baigent C.
- Blackwell L.
- Emberson J.
- Holland L.E.
- Reith C.
- Bhala N.
- Peto R.
- Barnes E.H.
- Keech A.
- et al.
- Juhola J.
- Magnussen C.G.
- Viikari J.S.
- Kahonen M.
- Hutri-Kahonen N.
- Jula A.
- Lehtimaki T.
- Akerblom H.K.
- Pietikainen M.
- Laitinen T.
- et al.
MATERIALS AND METHODS
Design and study population

Genetic data
Lipid measurements
Statistical analysis
where n is the number of SNPs, β is the effect size reported in the adult GWAS (weight), and SNP represents the number of trait-increasing alleles (dosage) from the Generation R GWAS data for that SNP. So for each SNP, the dosage of the trait-increasing allele from the Generation R GWAS data was multiplied by the effect size from the adult GWAS and these values were then summed across all SNPs in the GRS. Next, we rescaled the weighted risk scores to range from zero to the maximum number of trait-increasing alleles, which equals two times the number of SNPs in the score using the following formula: Rescaled GRS = (weighted GRS × maximum number of trait-increasing alleles)/(2 × sum of weights). For the figures, the risk scores were rounded to the nearest integer for clarity of presentation. Third, we created unweighted risk scores by summing the number of trait-increasing alleles for all SNPs in the score using the dosage data. We studied the associations of weighted and unweighted GRSs with all outcomes using multiple linear regression models.
Expression quantitative trait loci analysis
RESULTS
Characteristics of the study population
Characteristics | Full Group (N = 2,645) | Europeans (N = 1,372) |
---|---|---|
Birth | ||
Boys (%) | 50.7 | 50.9 |
Gestational age (weeks) | 40.0 (1.6) | 40.1 (1.5) |
Weight birth (g) | 3,462 (517) | 3,551 (517) |
Childhood | ||
Age at lipid measurements (years) | 6.0 (5.7, 7.3) | 6.0 (5.7, 6.8) |
BMI (kg/m2) | 16.2 (1.8) | 15.9 (1.4) |
TC (mmol/l) | 4.2 (0.7) | 4.2 (0.6) |
HDL-C (mmol/l) | 1.3 (0.3) | 1.3 (0.3) |
LDL-C (mmol/l) | 2.4 (0.6) | 2.4 (0.6) |
TG (mmol/l)a | 0.94 (0.45, 2.02) | 0.96 (0.45, 2.06) |
Associations of SNPs for TG with childhood lipid levels
Ln TG (mmol/l) | TC (mmol/l) | LDL-C (mmol/l) | HDL-C (mmol/l) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Difference (SE) | P | Explained Variance (%) | Difference (SE) | P | Explained Variance (%) | Difference (SE) | P | Explained Variance (%) | Difference (SE) | P | Explained Variance (%) | |
TG GRS | 0.020 (0.002) | 6.63E−18 | 2.8 | 0.005 (0.003) | 0.12 | 0.1 | 0.005 (0.003) | 0.09 | 0.1 | −0.006 (0.002) | 4.75E−4 | 0.4 |
TC GRS | 0.003 (0.002) | 0.23 | 0.05 | 0.021 (0.003) | 2.86E−10 | 1.5 | 0.018 (0.003) | 1.80E−9 | 1.3 | 0.003 (0.002) | 0.09 | 0.1 |
LDL-C GRS | 0.004 (0.002) | 0.07 | 0.12 | 0.022 (0.004) | 7.68E−10 | 1.4 | 0.026 (0.003) | 1.26E−16 | 2.5 | −0.005 (0.002) | 0.002 | 0.4 |
HDL-C GRS | −0.005 (0.002) | 4.38E−4 | 0.4 | 0.010 (0.002) | 2.00E−6 | 0.2 | −0.005 (0.002) | 0.006 | 0.3 | 0.017 (0.001) | 1.92E−62 | 9.7 |

Associations of SNPs for TC with childhood lipid levels
Associations of SNPs for LDL-C with childhood lipid levels
Associations of SNPs for HDL-C with childhood lipid levels
Associations in children of European ancestry
eQTL analysis
DISCUSSION
Interpretation of the main findings
- Juhola J.
- Magnussen C.G.
- Viikari J.S.
- Kahonen M.
- Hutri-Kahonen N.
- Jula A.
- Lehtimaki T.
- Akerblom H.K.
- Pietikainen M.
- Laitinen T.
- et al.
- Lutsey P.L.
- Rasmussen-Torvik L.J.
- Pankow J.S.
- Alonso A.
- Smolenski D.J.
- Tang W.
- Coresh J.
- Volcik K.A.
- Ballantyne C.M.
- Boerwinkle E.
- et al.
- Sovio U.
- Mook-Kanamori D.O.
- Warrington N.M.
- Lawrence R.
- Briollais L.
- Palmer C.N.
- Cecil J.
- Sandling J.K.
- Syvanen A.C.
- Kaakinen M.
- et al.
- Weinstock P.H.
- Bisgaier C.L.
- Aalto-Setala K.
- Radner H.
- Ramakrishnan R.
- Levak-Frank S.
- Essenburg A.D.
- Zechner R.
- Breslow J.L.
- Henderson H.E.
- Kastelein J.J.
- Zwinderman A.H.
- Gagne E.
- Jukema J.W.
- Reymer P.W.
- Groenemeyer B.E.
- Lie K.I.
- Bruschke A.V.
- Hayden M.R.
- et al.
- Rip J.
- Nierman M.C.
- Wareham N.J.
- Luben R.
- Bingham S.A.
- Day N.E.
- van Miert J.N.
- Hutten B.A.
- Kastelein J.J.
- Kuivenhoven J.A.
- et al.
Methodological considerations
CONCLUSIONS
Acknowledgments
REFERENCES
- Cardiovascular diseases (CVDs). 2015; (Accessed July 20, 2015, at http://www.who.int/mediacentre/factsheets/fs317/en/)
- Prediction of coronary heart disease using risk factor categories.Circulation. 1998; 97: 1837-1847
- Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.Lancet. 2007; 370: 1829-1839
- Major lipids, apolipoproteins, and risk of vascular disease.JAMA. 2009; 302: 1993-2000
- Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.Circulation. 2007; 115: 450-458
- Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up.J. Intern. Med. 2011; 270: 65-75
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.Lancet. 2010; 376: 1670-1681
- A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study.BMC Med. Genet. 2007; 8: S17
- Discovery and refinement of loci associated with lipid levels.Nat. Genet. 2013; 45
- Biological, clinical and population relevance of 95 loci for blood lipids.Nature. 2010; 466: 707-713
- Examination of genetic variants influencing lipid traits in pediatric populations.J. Pediatr. Genet. 2012; 1: 85-98
- Association of known loci with lipid levels among children and prediction of dyslipidemia in adults.Circ Cardiovasc Genet. 2011; 4: 673-680
- Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study.J. Pediatr. 2011; 159: 584-590
- The Generation R Study: design and cohort update 2012.Eur. J. Epidemiol. 2012; 27: 739-756
- Challenges in conducting genome-wide association studies in highly admixed multi-ethnic populations: the Generation R Study.Eur. J. Epidemiol. 2015; 30: 317-330
- The Generation R Study: Biobank update 2015.Eur. J. Epidemiol. 2014; 29: 911-927
- Genotype imputation.Annu. Rev. Genomics Hum. Genet. 2009; 10: 387-406
- MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes.Genet. Epidemiol. 2010; 34: 816-834
- The International HapMap Project.Nature. 2003; 426: 789-796
- A haplotype map of the human genome.Nature. 2005; 437: 1299-1320
- Systematic identification of trans eQTLs as putative drivers of known disease associations.Nat. Genet. 2013; 45: 1238-1243
- Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study.Circ Cardiovasc Genet. 2012; 5: 73-80
- Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies.Eur. Heart J. 2013; 34: 972-981
- Genetic determinants of long-term changes in blood lipid concentrations: 10-year follow-up of the GLACIER study.PLoS Genet. 2014; 10: e1004388
- Trends in serum lipid levels during 1980–1992 in children and young adults. The Cardiovascular Risk in Young Finns Study.Am. J. Epidemiol. 1997; 146: 64-77
- Fasting might not be necessary before lipid screening: a nationally representative cross-sectional study.Pediatrics. 2011; 128: 463-470
- Association between common variation at the FTO locus and changes in body mass index from infancy to late childhood: the complex nature of genetic association through growth and development.PLoS Genet. 2011; 7: e1001307
- Deficiency of the zinc finger protein ZPR1 causes neurodegeneration.Proc. Natl. Acad. Sci. USA. 2006; 103: 7471-7475
- Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes.J. Clin. Invest. 1995; 96: 2555-2568
- Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins.J. Lipid Res. 1999; 40: 735-743
- Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 637-642
- Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.J. Lipid Res. 2005; 46: 297-306
- Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.Eur. Heart J. 2013; 34: 982-992
- Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.JAMA. 2008; 299: 2777-2788
- A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.Nature. 2000; 406: 203-207
- Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study.Circ Cardiovasc Genet. 2009; 2: 26-33
- A meta-analysis of genome-wide association studies for adiponectin levels in East Asians identifies a novel locus near WDR11-FGFR2.Hum. Mol. Genet. 2014; 23: 1108-1119
- Structure of the human hepatic triglyceride lipase gene.Biochemistry. 1989; 28: 8966-8971
- The ABCs of cholesterol efflux.Nat. Genet. 1999; 22: 316-318
- The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway.J. Clin. Invest. 1999; 104: R25-R31
- Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis.PLoS Genet. 2009; 5: e1000730
Article info
Publication history
Footnotes
The general design of the Generation R Study was made possible by financial support from Erasmus Medical Center, Rotterdam, Erasmus University Rotterdam, Netherlands Organisation for Health Research and Development (ZonMw), Netherlands Organisation for Scientific Research (NWO), the Dutch Ministry of Health, Welfare and Sport, and the Ministry of Youth and Families. Other support was provided by Netherlands Organisation for Health Research and Development (VIDI 016.136.361) and a European Research Council Consolidator Grant (ERC-2014-CoG-648916) (V.W.V.J.), and European Union's Horizon 2020 Research and Innovation Programme Grant 633595 (DynaHEALTH) (J.F.F). The Generation R Study received funding from the European Union's Horizon 2020 Research and Innovation Programme (733206, LIFECYCLE). O.H.F. works in ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc., and AXA. None of these funders had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The authors declare no financial conflicts of interest.
Abbreviations: CAD
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy